Scarica l'app Stockscreener
14.28
0.21%
0.03
Dopo l'orario di chiusura:
14.30
0.02
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? - sharewise.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at Guggenheim - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Amicus Therapeutics Inc AM6 Stock Analysis and Forecast - earlytimes.in
BioMarin's $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - FinancialContent
Amicus Therapeutics Earnings Notes - Trefis
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Can Religare Enterprises Limited Stock Deliver Alpha in a Choppy MarketFundamental Stock Analysis & Free Navigate Market With Precision - earlytimes.in
Amicus Therapeutics (NASDAQ:FOLD) Nasdaq 100 Index Precision Biotech - Kalkine Media
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
FOLD: Analyst Downgrade and Price Target Adjustments | FOLD Stoc - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by Leerink Partners - MarketBeat
Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17 - marketscreener.com
Leerink Partners downgrades Amicus Therapeutics stock on BioMarin acquisition By Investing.com - Investing.com UK
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc.FOLD - The AI Journal
Voya Investment Management LLC Sells 90,062 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Amicus Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:BMRN) 2025-12-24 - Seeking Alpha
John F. Crowley: A Legacy For Rare Diseases - Oncodaily
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Is the Market Bullish or Bearish on Amicus Therapeutics Inc? - Benzinga
Published on: 2025-12-24 04:19:57 - Bollywood Helpline
Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,642 Shares - MarketBeat
Amicus Therapeutics Executive Sells Shares Under Trading Plan - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
BioMarin To Buy Amicus For $4.8 Billion - Pulse 2.0
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSECWAN), Katapult Holdings, Inc. (NasdaqKPLT), Janus Henderson Group plc (NYSEJHG), Amicus Therapeutics, Inc. (Nasdaq - GlobeNewswire Inc.
What's Going On With BioMarin Stock On Tuesday? - Sahm
Promising Biotech Stocks To Follow NowDecember 19th - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by Citigroup to "Hold" - MarketBeat
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Citigroup downgrades Amicus Therapeutics (FOLD) - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion By Investing.com - Investing.com Nigeria
Amicus Therapeutics Inc. (FOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Amicus Therapeutics (NASDAQ:FOLD) Sees Strong Trading VolumeHere's Why - MarketBeat
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025) - ts2.tech
American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha
The Biotech Growth Trust PLCBioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics - Research Tree
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):